Spirapril
Also known as: BAY 73‑7839, Renormax, SCH-33861, Spirapril
Source Spirapril at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Spirapril is an oral prodrug ACE inhibitor used for hypertension and heart failure; it is activated to the dipeptide-like inhibitor spiraprilat.
Mechanism of Action
Prodrug converted to spiraprilat, which competitively inhibits angiotensin‑converting enzyme, decreasing formation of angiotensin II and aldosterone, leading to vasodilation and reduced blood pressure.
Routes of Administration
Goals & Uses
- Heart failureCardiovascularModerate
- Hypertension managementCardiovascularHigh
- Renoprotection in chronic kidney diseaseNephrologyLow
- HypertensionCardiovascularHigh
Contraindications
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- History of ACE inhibitor-induced angioedemaImmunologic/AllergicHigh
- Severe hypersensitivity to spirapril or excipientsAllergyHigh
- Concurrent use of aliskiren in diabetic patientsDrug InteractionHigh
- Bilateral renal artery stenosisVascular/RenalHigh
Adverse Effects
- CoughRespiratoryCommonPersistent or episodic cough
- HypotensionCardiovascularUncommonLow blood pressure
- Hypotension (first-dose effect)CardiovascularCommon
- Renal impairmentRenalUncommon
- HyperkalemiaElectrolyte ImbalanceUncommon
- Dry coughRespiratoryCommon
- AngioedemaImmunologicRare
- Dizziness/headacheNeurologicalCommon
Drug Interactions
- Potassium‑sparing diuretics (e.g., spironolactone)Moderate
- Potassium-sparing diuretics (e.g., spironolactone, amiloride)High
- AliskirenHigh
- NSAIDsLowMay increase renal risk in susceptible patients
- Antidiabetic agents (insulin, sulfonylureas)Moderate
- LithiumHigh
Population Constraints
- Renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- ElderlyAgeRelative
- Patients with severe renal artery stenosisRenalAbsolute
- Patients with severe hepatic impairmentHepaticRelative
- Elderly patientsAgeRelative
- Pregnant womenReproductiveAbsolute
Regulatory Status
- European UnionApprovedApproved: HypertensionApproved in several EU member states.
- JPApprovedApproved: Hypertension, Heart failureMarketed as Renormax.
- United StatesUnapprovedNot submitted for FDA approval.
- United KingdomUnknownLimited availability data post-Brexit; not a commonly listed product in MHRA databases.
Approved in Japan and several EU member states; not approved in the United States.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Spirapril?
Spirapril is an oral prodrug ACE inhibitor used for hypertension and heart failure; it is activated to the dipeptide-like inhibitor spiraprilat.
What is Spirapril used for?
Spirapril is educationally associated with: Heart failure, Hypertension management, Renoprotection in chronic kidney disease, Hypertension. Educational only — not medical advice.
How is Spirapril administered?
Recorded routes of administration: Oral.
What are the potential side effects of Spirapril?
Reported adverse effects include: Cough, Hypotension, Hypotension (first-dose effect), Renal impairment, Hyperkalemia, Dry cough, Angioedema, Dizziness/headache. This list is not exhaustive — consult a qualified clinician.
Who should avoid Spirapril?
Recorded contraindications: Pregnancy, History of ACE inhibitor-induced angioedema, Severe hypersensitivity to spirapril or excipients, Concurrent use of aliskiren in diabetic patients, Bilateral renal artery stenosis. Consult a qualified clinician before use.